清脆的
效应器
遗传增强
生物
纤维化
计算生物学
Cas9
基因
生物信息学
癌症研究
医学
遗传学
免疫学
病理
作者
Nianan Luo,Wenjun Zhong,Emma Johnson,Jianguo Lu,Rui Dong
标识
DOI:10.1007/s11033-022-07713-6
摘要
Hepatic fibrosis is a pathological reaction of tissue damage and repair caused by various pathogenic factors acting on liver. At present, there is no effective anti-fibrotic specific therapy. Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (dCas9) system is a new generation of gene editing technology. The CRISPR/dCas9 system provides a platform for studying site-specific transcriptional regulation, which has high efficiency in gene transcriptional activation for achieving robust. This system holds promise for hepatic fibrosis therapy via acting on liver fibrosis effector cells. However, there are some challenges associated with this novel technology, such as large structural variants at on-target, off-target sites, and targeted delivery efficiency. In this review, we present the potential implications and describe the challenges of CRISPR/dCas9 system that might be encountered in hepatic fibrosis therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI